Literature DB >> 14558111

Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab.

M Vis, G J Wolbink, M C Lodder, P J Kostense, R J van de Stadt, M H M T de Koning, B A C Dijkmans, W F Lems.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14558111     DOI： 10.1002/art.11292

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  19 in total

1.  Inflammatory factors in the circulation of patients with active rheumatoid arthritis stimulate osteoclastogenesis via endogenous cytokine production by osteoblasts.

Authors:  J L Pathak; N Bravenboer; P Verschueren; W F Lems; F P Luyten; J Klein-Nulend; A D Bakker
Journal:  Osteoporos Int       Date:  2014-07-16       Impact factor: 4.507

Review 2.  Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.

Authors:  C B Confavreux; R D Chapurlat
Journal:  Osteoporos Int       Date:  2010-10-20       Impact factor: 4.507

3.  Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment.

Authors:  K Briot; P Garnero; A Le Henanff; M Dougados; C Roux
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

4.  Incidence and risk factors for vertebral fracture in rheumatoid arthritis: an update meta-analysis.

Authors:  Yang Liu; Jun Jiang; Minmin Mo; Xiaohong Sun; Kailong Yu
Journal:  Clin Rheumatol       Date:  2022-01-10       Impact factor: 2.980

5.  Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.

Authors:  Katalin Gulyás; Ágnes Horváth; Edit Végh; Anita Pusztai; Ágnes Szentpétery; Zsófia Pethö; Andrea Váncsa; Nóra Bodnár; Péter Csomor; Attila Hamar; Levente Bodoki; Harjit Pal Bhattoa; Balázs Juhász; Zoltán Nagy; Katalin Hodosi; Tamás Karosi; Oliver FitzGerald; Gabriella Szücs; Zoltán Szekanecz; Szilvia Szamosi; Sándor Szántó
Journal:  Clin Rheumatol       Date:  2019-09-14       Impact factor: 2.980

Review 6.  Biologic therapies and bone loss in rheumatoid arthritis.

Authors:  C A F Zerbini; P Clark; L Mendez-Sanchez; R M R Pereira; O D Messina; C R Uña; J D Adachi; W F Lems; C Cooper; N E Lane
Journal:  Osteoporos Int       Date:  2016-10-31       Impact factor: 4.507

Review 7.  Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Authors:  Harjit P Bhattoa; Zoltán Szekanecz; Boglárka Soós; Ágnes Szentpétery; Hennie G Raterman; Willem F Lems
Journal:  Nat Rev Rheumatol       Date:  2022-03-10       Impact factor: 20.543

8.  Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo.

Authors:  Arno W R van Kuijk; Jeroen DeGroot; Rishma C Koeman; Nico Sakkee; Dominique L Baeten; Danielle M Gerlag; Paul P Tak
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

9.  Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.

Authors:  Hubert Marotte; Pierre Miossec
Journal:  Biologics       Date:  2008-12

10.  Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.

Authors:  C A Wijbrandts; R Klaasen; M G W Dijkgraaf; D M Gerlag; B L F van Eck-Smit; P P Tak
Journal:  Ann Rheum Dis       Date:  2008-04-13       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.